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Abstract: Background  No specific antiviral has been proven effective for treatment of severe
COVID-19. Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory
effects on pathogenic animal and human coronaviruses, including SARS-CoV-2 in
vitro, and inhibits MERS-CoV and SARS-CoV replication and disease in animal
models.
Methods:  We conducted a randomized, double-blind, placebo-controlled, multicentre
trial. Adults hospitalized with laboratory confirmed SARS-CoV-2 infection, and interval
from illness onset to enrollment of ≤12 days, SaO  2  ≤94% on room air or a PaO  2
/FiO  2  ratio less than 300mmHg, and radiologically confirmed pneumonia were
randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed
by 100 mg on days 2-9 in single daily infusions), or placebo for 10 days. Subjects were
permitted the use of lopinavir-ritonavir. The primary endpoint was time to clinical
improvement (censored at Day 28), defined as the time (in days) from randomization to
study treatment (remdesivir or placebo) until a decline of two categories on a six-
category ordinal scale of clinical status (1  discharged; 6  death) or discharged alive
from hospital, whichever came first. This trial is registered with ClinicalTrials.gov,
number NCT04257656.
Findings:  237 patients with laboratory-confirmed COVID-19 underwent randomization
(158 remdesivir; 79 control); one patient in the control group withdrew before receiving
any study treatment. Remdesivir use was not associated with a difference in time to
clinical improvement (hazard ratio 1.23, 95% CI 0.87-1.75), mortality at 28 days (13.9%
vs 12.8%, difference 1.1; 95% CI, -8.1, 10.3), or in time to SARS-CoV-2 PCR
negativity. Adverse events were reported in 65.2% of remdesivir recipients versus
64.1% in placebo recipients. Remdesvir was stopped early in 18 (11.6%) patients
because of adverse effects, compared to 4 (5.1%) in the control group.
Interpretation:  In this study of hospitalized adult patients with severe COVID-19 that
was terminated prematurely, remdesivir was not associated with clinical or virological
benefits.
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Research in context 
Evidence before this study 
We searched PubMed database, up to April 10, 2020, for published clinical trials evaluating the 
effect of remdesivir among patients with laboratory confirmed coronavirus disease 2019 
(COVID-19). The search terms used were (“COVID-19” OR “2019-nCoV” or “SARS-CoV-2”) 
AND “remdesivir” AND (“clinical trial” or “randomized controlled trial”). We identified no 
published clinical trials of the effect of remdesivir in patients with COVID-19. 
Added value of this study 
Our study is the first randomized, double-blind, placebo-controlled clinical trial evaluating the 
effect of intravenous remdesivir in adults hospitalized with severe COVID-19. The study was 
terminated before attaining the pre-specified sample size and was underpowered for an efficacy 
evaluation. In the intention-to-treat population, the primary endpoint of time to clinical 
improvement was numerically shorter in the remdesivir group compared to the control group 
(median 21.0 days vs. 23 days), but was not statistically significant different (hazard ratio 1.23; 
95% CI 0.87 to 1.75). For other secondary endpoints, including 28-day mortality, duration of 
invasive mechanical ventilation, and time to SARS-CoV-2 PCR negativity, no statistically 
significant differences were observed. 
Implications of all the available evidence 
No significant benefits were observed for remdesvir treatment beyond standard of care. Our trial 
did not attain the predetermined sample size because the outbreak of COVID-19 was brought 
under control in China. Future studies of remdesivir, including earlier treatment in COVID-19 
patients and higher dose regimens or in combination with other antivirals or SARS-CoV-2 
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neutralizing antibodies in those with severe COVID-19 are needed to better understand its 






Background No specific antiviral has been proven effective for treatment of severe COVID-19. 
Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic 
animal and human coronaviruses, including SARS-CoV-2 in vitro, and inhibits MERS-CoV and 
SARS-CoV replication and disease in animal models.  
Methods: We conducted a randomized, double-blind, placebo-controlled, multicentre trial. 
Adults hospitalized with laboratory confirmed SARS-CoV-2 infection, and interval from illness 
onset to enrollment of ≤12 days, SaO2 ≤94% on room air or a PaO2/FiO2 ratio less than 
300mmHg, and radiologically confirmed pneumonia were randomly assigned in a 2:1 ratio to 
intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2-9 in single daily 
infusions), or placebo for 10 days. Subjects were permitted the use of lopinavir-ritonavir. The 
primary endpoint was time to clinical improvement (censored at Day 28), defined as the time (in 
days) from randomization to study treatment (remdesivir or placebo) until a decline of two 
categories on a six-category ordinal scale of clinical status (1 ꞊ discharged; 6 ꞊ death) or 
discharged alive from hospital, whichever came first. This trial is registered with 
ClinicalTrials.gov, number NCT04257656.  
Findings: 237 patients with laboratory-confirmed COVID-19 underwent randomization (158 
remdesivir; 79 control); one patient in the control group withdrew before receiving any study 
treatment. Remdesivir use was not associated with a difference in time to clinical improvement 
(hazard ratio 1.23, 95% CI 0.87-1.75), mortality at 28 days (13.9% vs 12.8%, difference 1.1; 
95% CI, -8.1, 10.3), or in time to SARS-CoV-2 PCR negativity. Adverse events were reported in 
65.2% of remdesivir recipients versus 64.1% in placebo recipients. Remdesvir was stopped early 
in 18 (11.6%) patients because of adverse effects, compared to 4 (5.1%) in the control group. 
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Interpretation: In this study of hospitalized adult patients with severe COVID-19 that was 
terminated prematurely, remdesivir was not associated with clinical or virological benefits.  
Funding: Chinese Academy of Medical Sciences (CAMS) Emergency Project of COVID-19 
(2020HY320001); National Key Research and Development Program of China 
(2018YFC1200102); The Beijing Science and Technology Project (Z19110700660000). 





The ongoing pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) 
infections has caused over 1,777,666 illnesses and 108,867 deaths globally as of 12 April 20201.  
Although most infections are self-limited, approximately 15% of infected adults develop severe 
pneumonia that requires treatment with supplemental oxygen and an additional 5% progress to 
critical illness with hypoxemic respiratory failure, acute respiratory distress syndrome, and multi-
organ failure that necessitates ventilatory support, often for several weeks 2–4. One-half or more of 
patients with coronavirus infectious disease-2019 (COVID-19) patients requiring invasive 
mechanical ventilation have died in hospital 4,5, and the associated burden on healthcare systems, 
especially intensive care units, has been overwhelming in several affected countries.   
Although several approved drugs and investigational agents have shown antiviral activity against 
SARS-CoV-2 in vitro 6,7, at present there are no antiviral therapies of proven value in treating 
severely ill COVID-19 patients.  Small observational studies enrolling predominantly those with 
mild illness have reported possible clinical benefit of hydroxychoroquine (alone or combined with 
azithromycin)8. An RCT enrolling patients within 12 days of symptom onset found that favipiravir 
was superior to arbidol in the proportion of those with mild illness who had recovered clinically 
by day 7 (56% vs 71%), but not in those with critical illness (0 vs 6%) 9.  In severe illness, one 
uncontrolled study of five patients given convalescent plasma suggested possible benefit, although 
the patients already had detectable anti-SARS-CoV-2 neutralizing antibodies before receipt of the 
plasma 10. An open-label RCT of oral lopinavir-ritonavir found no significant effect on the primary 
outcome measure of time to clinical improvement (median, 16 days) and no evidence of reduction 
in viral RNA titers compared to control 11. However, per-protocol analyses suggested possible 
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reductions in time to clinical improvement (difference of 1 day), particularly in those treated within 
12 days of symptom onset.  Further studies of lopinavir-ritonavir and other agents are ongoing.  
Remdesivir (also GS-5734) is monophosphoramidate prodrug of an adenosine analog that has a 
broad antiviral spectrum including filo-, paramyxo-, pneumo- and coronaviruses 12,13.  Remdesivir 
is inhibitory in vitro for all human and animal coronaviruses tested to date including SARS-CoV-
2 13–15 and has shown antiviral and clinical effects in animal models of SARS-CoV and Middle 
East Respiratory Syndrome (MERS)-CoV infections 13,16,17. In a lethal murine model of MERS, 
remdesivir was superior to a regimen of combined interferon-beta and lopinavir-ritonavir 16. 
Remdesivir is a potent inhibitor of SARS-CoV-2 replication in human nasal and bronchial airway 
epithelial cells 18.  Intravenous remdesivir was studied for treatment of Ebola virus disease, in 
which it was adequately tolerated but less effective than several monoclonal antibody therapeutics 
19, and has been used through individual compassionate use basis in over the last several months 
in certain countries to date 20. Case studies have suggested benefit in severely ill COVID-19 
patients 5,20,21. However, the clinical and antiviral efficacy of remdesivir remains to be established. 
Here we report the results of an RCT of remdesivir in severe COVID-19 illness.   
METHODS 
Trial design and oversight 
This was an investigator-initiated, individually randomized, placebo-controlled, double-blind trial 
to evaluate the efficacy and safety of intravenous remdesivir planned in 453 adults (≥18 years) 
hospitalized with severe COVID-19 illness. The trial was conducted from 6 February to 1 April 
2020 at nine hospitals in Wuhan, Hubei Province, People’s Republic of China (see Supplementary 
Appendix). Eligible patients were randomized 2:1 to either intravenous remdesivir (200 mg on day 
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1 followed by 100 mg on days 2-9 in single daily infusions) or placebo infusions for a total of 10 
days (both provided by Gilead Sciences, Foster City, California). Randomization was stratified 
according to the level of respiratory support: (1) no oxygen support or oxygen support with nasal 
duct or mask; (2) high-flow oxygen, non-invasive ventilation, invasive ventilation, or extra-
corporeal membrane oxygenation (ECMO). The permuted block (30 patients per block) 
randomization sequence, including stratification, was prepared by a statistician not involved in the 
trial using SAS software, version 9.4 (SAS Institute). Eligible patients were allocated to receive 
medication in individually numbered packs, according to the sequential order of the randomization 
centre (Jin Yin-Tan Hospital central pharmacy). Envelopes were prepared for emergency 
unbinding. 
The trial was approved by the institutional review boards of each participating hospital. Written 
informed consent was obtained from all patients, or their legal representative if they were too 
unwell to provide consent. The trial was conducted in accordance with the principles of the 
Declaration of Helsinki and the International Conference on Harmonization–Good Clinical 
Practice guidelines.  
Patients  
Males and non-pregnant female patients aged ≥18 years were eligible if they were RT-PCR 
positive for SARS-CoV-2, had pneumonia confirmed by chest imaging, had a SaO2 ≤94% on 
room air or a PaO2/FiO2 ratio ≤300mgHg, and were within 12 days of illness onset.  Eligible 
subjects of child-bearing age (male or female) agreed to take effective contraceptive measures 
(including hormonal contraception, barrier methods or abstinence) during the study period and for 
at least 7 days following the last study drug administration. Exclusion criteria included pregnancy 
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or breast-feeding; hepatic cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase 
(AST) elevated over 5 times the ULN; known severe renal impairment (estimated eGFR< 30 
mL/min/1.73m2), or having received continuous renal replacement therapy (CRRT), hemodialysis 
or peritoneal dialysis; possibility of transfer to a non-study hospital within 72h; and enrollment 
into an investigational treatment study for COVID-19 within 30 days prior to screening. The use 
of other treatments, including lopinavir-ritonavir, was permitted. 
Clinical and laboratory monitoring 
Patients were assessed once daily by trained nurses using diary cards that captured data on a 6-
category ordinal scale and safety from day 0 to day 28, hospital discharge, or death.  Other clinical 
data was recorded using the World Health organization (WHO) - International Severe Acute 
Respiratory and Emerging Infections Consortium (ISARIC) case record form 22. The safety 
evaluation included daily monitoring for adverse events (AEs), clinical laboratory testing (days 1, 
3, 7 and 10), 12-lead electrocardiogram (ECG)(days 1, 14), and daily vital signs measurements 
(see Protocol for details23).  Clinical data were recorded on paper case record forms and then double 
entered into an electronic database and validated by trial staff. Nasopharyngeal or oropharyngeal 
swabs, lower respiratory tract samples (sputum/tracheal aspiration/alveolar lavage fluid) as 
available, and fecal/anal swab specimens were collected on days 1, 3, 5, 7, 10, 14, 21, and 28 for 
viral RNA detection and quantification.  
The trial was monitored by a contract research organization (Hangzhou Tigermed Consulting Co., 
Ltd24). Virologic testing was done at Teddy Clinical Research Laboratory (Tigermed- DiAn Joint 
Venture) using quantitative real-time RT-PCR. RNA was extracted from clinical samples with the 
MagNA Pure 96 system, detected and quantified by Cobas z480 qPCR (Roche, switzerland), using 
LightMix Modular SARS-CoV-2 assays (TIB MOBIOL, Berlin, Germany). Baseline the upper 
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(nasopharyngeal, NP or Oropharyngeal swabs, OP) and lower respiratory tract specimens were 
tested for detection of E gene, RdRp gene and N gene, then samples on the subsequent visits were 
quantitatively and qualitative detected for E gene.   
Outcome measures 
The primary clinical endpoint was time to clinical improvement (TTCI) within 28 days after 
randomization. Clinical improvement was defined as a 2-point reduction in subjects' admission 
status on a 6-point ordinal scale, or live discharge from the hospital, whichever came first. The 6 
point scale included death: 6; hospitalized for ECMO and/or mechanical ventilation: 5; 
hospitalized for noninvasive ventilation and/or high flow oxygen therapy: 4; hospitalized for 
oxygen therapy (but not requiring high flow or noninvasive ventilation): 3; hospitalization but not 
requiring oxygen therapy: 2; discharged or having reached discharge criteria (defined as clinical 
recovery, i.e., normalization of pyrexia, respiratory rate [< 24/minute], and SpO2 [>94% on room 
air], and relief of cough, all maintained for at least 72 hours): 1. The 6-point scale was modified 
from the 7-point scale used in our previous COVID-19 lopinavir-ritonavir treatment11 by 
collapsing the two outpatient strata into one.  
Secondary outcomes included the proportions of subjects in each category of the 6-point scale 
within 7, 14, and 28 days of randomization; all-cause mortality within 28 days; frequency of 
invasive mechanical ventilation; duration of oxygen therapy; duration of hospitalization; and 
incidence of nosocomial infection (see Supplementary Appendix). Virologic measures included 
the proportions with viral RNA detection over time and viral RNA titer area-under-the-curve 
(AUC) measurements. Safety outcomes included treatment-emergent adverse events (AEs), 




The original design required a total of 325 events across both arms, since this would provide 80% 
power under a one-sided type I error of 2.5% if the hazard ratio comparing remdesivir to placebo 
is 1.4 which corresponds to a change in TTCI to 15 days assuming that TTCI is 21 days on placebo.  
One interim analysis using triangular boundaries25 and a 2:1 allocation ratio between remdesivir 
and placebo has been accounted for in the original design. Assuming an 80% event rate within 28 
days across both arms and a drop-out rate of 10% implies that approximately 453 patients were to 
be recruited for this trial (151 on placebo and 302 on remdesivir). The possibility for an interim 
analysis after enrollment of approximately 240 subjects was included in the design if requested by 
the independent data safety and monitoring board (DSMB). However, no subjects were enrolled 
after 12 March 2020 due to the control of the outbreak in Wuhan, and on 29 March the DSMB 
recommended that the study be terminated and analyzed. When all the other assumptions stayed 
the same, with the actual enrolment of 236 participants, the statistical power reduced from 80% to 
58%. 
The primary efficacy analysis was on an intention-to-treat (ITT) basis with all randomized patients. 
TTCI was assessed after all patients had reached Day 28; failure to reach clinical improvement or 
death before Day 28 were considered as right-censored at day 28. TTCI was portrayed by Kaplan-
Meier plot and compared with a log-rank test. The hazard ratio (HR) 95% confidence intervals 
(CI) for clinical improvement and hazard ratio with 95% CI for clinical deterioration was 
calculated by Cox proportional-hazards model. Other analyses include subgroup analyses for those 
randomized ≤10 or >10 days after illness onset, time-to-clinical deterioration (defined as one 
category increase or death), and for viral RNA load at entry. We present adverse event data on the 
patients’ actual treatment exposure, coded using Medical Dictionary for Regulatory Activities 
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(MedDRA). Statistical analyses were conducted using SAS software, version 9.4 (SAS Institute 
Inc.).  
This trial is registered with ClinicalTrials.gov, number NCT04257656. 
RESULTS 
Patients 
Among 255 patients who were screened, 237 patients were eligible, consented and were 
randomized, of whom 1 withdrew. 158 were assigned to receive remdesivir and 78 to receive 
placebo.  In the remdesivir group, 155 (98.1%) received remdesivir as assigned and placebo was 
given to all patients in the control group (Figure 1). The median age of study patients was 65 years 
(interquartile range [IQR], 56 to 71 years) and 140 (59.3%) were males. The most common 
comorbidity was hypertension (43.2%), followed by diabetes (23.7%) and coronary heart disease 
(7.2%). Lopinavir-ritonavir was co-administered in 42 (17.8%) patients at day 1 (Table 1). Most 
patients (81.6% in the remdesivir and 83.3% in the control group) were in category 3 of the six-
point ordinal scale of clinical status at baseline. There were more patients (60.3%) in the control 
group than in the remdesivir group (44.3%) who had been symptomatic for 10 days or less at the 
time of randomization. No other major differences in symptoms, signs, laboratory results, disease 
severity, or treatments were observed between groups at baseline. 
The median days from illness onset to randomization was 10 days (IQR 9 to 12 days). No important 
differences were apparent between the groups in other treatments received (including lopinavir-
ritonavir or corticosteroids) (Table 2).  During the whole period of hospitalization, 155 (65.7%) 
patients received corticosteroids, with the median time from illness onset to corticosteroids therapy 
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being 8.5 days (IQR, 6.5 to 11.0 days), while 91 (38.6%) patients received corticosteroids before 
enrollment. 
Primary outcome 
In the intention-to-treat population, the time to clinical improvement in the remdesivir group was 
non-significantly shorter than the control group (median 21.0 days vs. 23 days; hazard ratio 1.23; 
95% CI 0.87 to 1.75) (Table 3 and Figure 2). Results for TTCI were similar in the per-protocol 
population (median 21.0 days vs, 23.0 days, respectively hazard ratio 1.27; 95% CI 0.89 to 1.80) 
(Table S1 and Figure S1).   Although not statistically significant, remdesivir was associated with 
a faster time to clinical improvement as compared to placebo among patients with symptom 
duration of 10 days or less in the intention-to-treat population (Figure S2). If clinical improvement 
was defined as a one, instead of two, category decline, the hazard ratio was 1.34 with 95% CI of 
0.96 to 1.86 (Figure S3). Time-to-clinical deterioration, defined as a one category increase or death, 
the hazard ratio was 0.95 with 95% CI of 0.55 to 1.64 (Figure S4). 
Secondary outcome 
The 28-day mortality was similar between the two groups (13.9% in remdesivir vs. 12.8% in 
placebo; difference 1.1; 95% CI -8.1 to 10.3). Use of remdesivir within 10 days after symptom 
onset was associated with a non-significantly lower 28-day mortality (5.1% vs. 9.0%; difference -
3.9; 95% CI -11.1 to 3.3), while late use was non-significantly associated with a higher 28-day 
mortality (7.6% vs. 3.8%; difference 3.7; 95% CI -2.2 to 9.7). The clinical improvement rates at 
days 14 and day 28 were higher in remdesivir group but this was non-significant (26.6% vs. 23.1% 
at day 14; 65.2% vs. 57.7% at day 28). For patients assigned to remdesivir group, the invasive 
mechanical ventilation (IMV) duration was numerically shorter than those assigned to control 
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group (median 7.0 days vs. 15.5 days; difference 4.0 days; 95% CI -2.0 to 14.0 days) but the 
number of patients was small. No significant differences were observed between the two groups 
in length of oxygen support, hospital length of stay, days from randomization to discharge, days 
from randomization to death and distribution of six-category scale at day 7, day 14 and day 28. 
(Table 3 and Figure S5) 
Virology 
Of 236 patients who were RT-PCR positive at enrollment, 37 (15.7%) had undetectable viral RNA 
on the NP/OP swab taken after consent. The mean baseline viral load of NP/OP swabs was 4.7 ± 
2.8 log10 copies/mL in the remdesivir group and 4.7 ± 2.4 log10 copies/mL in the control group 
(Table 1). The viral load decreased over time equally in both groups (Figure 3A). No difference in 
viral load were observed when stratified by interval from illness onset to randomization (Figure 
S6 A&B). The findings of viral load reduction were similar by lower respiratory specimens (Figure 
3B) 
         The cumulative rate of undetectable viral RNA of NP/OP swabs by day 28 was 64.8%, and 
the proportion negative was similar among patients receiving remdesivir and those receiving 
placebo (day 3, 23.4% to 24.4%; day 5, 33.5% to 32.1%; day 7, 41.8% to 41.0%; day 10, 51.9% 
to 57.7%; day 14, 58.9% to 62.8%; day 21, 62.0% to 67.9%; day 28, 62.7% to 69.2%) (Table S2).  
Safety 
Adverse events were reported in 102 (65.8%) patients in the remdesivir group and 50 (64.1%) in 
the control group. The most common adverse events in the remdesivir group were constipation 
(13.5%), hypoalbuminemia (12.9%), hypokalemia (11.6%), anaemia (11.6%), thrombocytopenia 
(10.3%), and increased total bilirubin (9.7%), and in control group were hypoalbuminemia (15.4%), 
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constipation (15.4%), anaemia (15.4%), hypokalemia (14.1%), increased aspartate 
aminotransferase (11.5%), elevated blood lipids (10.3%), and increased total bilirubin (9.0%). A 
total of 28 (18.1%) serious adverse events were reported in the remdesivir group and 20 (25.6%) 
in the control group. More patients in the remdesivir group discontinued drug for adverse events 
or serious adverse events (11.6% vs. 5.1%), among whom 7 (4.5%) were due to respiratory failure 
or ARDS in remdesivir group. All deaths during the observation period were judged by the site 
investigators to be unrelated to the intervention. (Table 4) 
 
DISCUSSION 
Our trial found that intravenous remdesivir did not significantly improve the time to clinical 
improvement (TTCI), mortality, or time to clearance of virus in patients with serious COVID-19 
illness compared to placebo. Compared to a recent study of compassionate use remdesivir that 
suggested clinical benefit20, our study population was not as ill ( at time of enrollment 0.4% on 
invasive mechanical ventilation or ECMO versus 64%) and was treated somewhat earlier in their 
disease course (median, 10 days versus 12 days).  Such differences might be expected to favor 
remdesivir providing greater effects in our study population, but we did not find this. However, 
our study did not reach its target enrollment because the stringent public health measures employed 
in Wuhan City led to marked reductions in new patient presentations in mid-March, and 
restrictions on hospital bed availability resulted in most patients being enrolled later in the course 
of disease. Consequently, we could not adequately assess whether earlier remdesivir treatment 
might have provided clinical benefit.  In one murine model of SARS, remdesivir treatment starting 
at 2 days post infection, after virus replication and lung airway epithelial damage had already 
peaked, significantly reduced SARS-CoV lung titers but did not decrease disease severity or 
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mortality 13. A need for early treatment has been found in nonhuman primate models of SARS and 
MERS in which virus replication is very short-lived and lung pathology appears to develop more 
rapidly than in human infections13,16,17. Such findings argue for testing of remdesivir earlier in 
COVID-19 illness.  
Remdesivir did not result in significant reductions in SARS-CoV-2 RNA loads or detectability in 
upper respiratory tract or sputum specimens in this study despite showing strong antiviral effects 
in pre-clinical models of CoV infection. In African green monkey kidney Vero E6 cells remdesivir 
inhibited SARS-CoV-2 with a 50% effective concentration (EC50) of 0.46 ug/ml and EC90 of 1.06 
ug/ml 6. In human nasal and bronchial airway epithelial (HAE) cells, a fixed 20 uM (12.1 ug/ml) 
concentration reduced estimated intracellular viral titers over 7.0 at 48 hours 18.  In human airway 
epithelial cells, remdesivir’s EC50 was 0.042 ug/ml for SARS-CoV and 0.045 ug/ml for MERS-
CoV 13. In a murine model of MERS subcutaneous remdesivir demonstrated significant antiviral 
and clinical effects with a dose regimen that maintained plasma concentrations above 1 uM (0.60 
ug/ml) throughout the dosing interval 13.  In rhesus macaques a 5 mg/kg dose, reported to be 
roughly equivalent to 100-mg daily dosing in humans, was effective for treatment of MERS-CoV 
infection and reduced pulmonary virus replication when started at 12 hours post infection 18. 
Healthy adult volunteers receiving a doses similar to our trial (200-mg on day, 100-mg on days 2-
4) had mean peak plasma concentrations of 5.4 ug/ml on day 1and 2.6 ug/ml on day 5. 26. Doses 
of 150 mg/day for 14 days have been adequately tolerated in healthy adults, and a daily dose regimen 
of 150 mg for 3 days followed by 225 mg for 11 days appeared to be generally well-tolerated in one patient 
with Ebola meningo-encephalitis 27. However, the pharmacokinetics of remdesivir in severely ill 
patients, and particularly the concentrations of the active nucleotide metabolite (GS-441524) 
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triphosphate in respiratory tract cells of treated patients, are unknown. Studies of higher dose 
regimens for which there are safety data (eg, 200 mg daily doses) warrant consideration.  
 
Our study found that remdesivir was adequately tolerated and no new safety concerns were 
identified. The overall proportion of patients with serious adverse events tended to be lower in 
remdesivir recipients compared to placebo (Table 3). However, a higher proportion of remdesivir 
recipients had dosing prematurely stopped by the investigators for adverse events (11.6% versus 
5.1% placebo) for various reasons including gastrointestinal symptoms (anorexia, nausea, 
vomiting), transaminase or bilirubin elevations, and worsened cardiopulmonary status.      
In addition to its diminished power to detect differences in clinical outcomes and initiation of 
treatment relatively late in COVID-19, our trial provided limited data on lower respiratory tract 
virus detection and lacked data on infectious virus recovery or on possible emergence of reduced 
susceptibility to remdesivir. Coronaviruses partially resistant to inhibition by remdesivir (~6-fold 
increased EC50) have been obtained following serial in vitro passage, but these viruses remain 
susceptible to higher remdesivir concentrations and show impaired fitness 28.  Another limitation 
of the trial was the high frequency of systemic corticosteroid use, which could have contributed to 
prolongation of viral replication, as observed in SARS 29 and MERS 30 and possibly diminished 
the likelihood of observing an antiviral effect with remdesivir.    
In summary we found that this dose regimen of intravenous remdesivir was adequately tolerated 
but did not provide significant clinical or antiviral effects in seriously ill COVID-19 patients. 
Future studies with larger sample sizes will continue to inform on remdesivir’s effect on COVID-
19. Furthermore, strategies to enhance remdesivir’s antiviral potency (e.g., higher dose regimens, 
combination with other antivirals or SARS-CoV-2 neutralizing antibodies) and to mitigate 
20 
 
immunopathologic host responses contributing to COVID-19 severity (e.g., inhibitors of IL-6, IL-
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Table 1. Baseline Demographic and Clinical Characteristics of the Patients 
Characteristics 
Total  
(n = 236) 
Remdesivir group 
 (n = 158) 
Control group  
(n = 78) 
Age, yr 65.0 (56.0-71.0) 66.0 (57.0-73.0) 64.0 (53.0-70.0) 
Gender, male, n (%) 140 (59.3)  89 (56.3)  51 (65.4) 
Any co-morbidities 167 (70.8) 112 (70.9) 55 (70.5) 
Hypertension 102 (43.2)  72 (45.6)  30 (38.5) 
Diabetes, n (%)  56 (23.7)  40 (25.3)  16 (20.5) 
Coronary heart disease, n (%)  17 (7.2)  15 (9.5)   2 (2.6) 
Body temperature, ℃ 36.8 (36.5-37.2) 36.8 (36.5-37.2) 36.8 (36.5-37.2) 
Fever, n (%)  87 (36.9)  56 (35.4)  31 (39.7) 
Respiratory rate > 24 /min, n (%)  47 (19.9)  36 (22.8)  11 (14.1) 
White blood cell count (× 109/L) 6.3 (4.5-8.3) 6.2 (4.4-8.3) 6.4 (4.5-8.3) 
    4-10, n (%) 166 (70.3) 108 (68.4)  58 (74.4) 
    <4, n (%)  39 (16.5)  27 (17.1)  12 (15.4) 
    >10, n (%)  28 (11.9)  20 (12.7)   8 (10.3) 
Lymphocyte count (× 109/L) 0.8 (0.6-1.1) 0.8 (0.6-1.1) 0.7 (0.6-1.2) 
    ≥ 1.0, n (%)  72 (30.5)  49 (31.0)  23 (29.5) 
    < 1.0, n (%) 161 (68.2) 106 (67.1)  55 (70.5) 
Platelet count (× 109/L) 187.0 (143.0-251.0) 183.0 (144.0-235.0) 194.5 (141.0-266.0) 
    ≥ 100, n (%) 223 (94.5) 148 (93.7)  75 (96.2) 
    < 100, n (%)  10 (4.2)   7 (4.4)   3 (3.8) 
Serum creatinine (μmol/L) 69.4 (56.0-84.3) 68.0 (56.0-82.0) 71.3 (56.0-88.7) 
    ≤ 133, n (%) 227 (96.2) 151 (95.6)  76 (97.4) 
    > 133, n (%)   5 (2.1)   3 (1.9)   2 (2.6) 
Aspartate aminotransferase (U/L) 32.0 (23.0-46.0) 31.0 (22.0-44.0) 33.0 (24.0-48.0) 
    ≤ 40, n (%) 158 (66.9) 109 (69.0)  49 (62.8) 
    > 40, n (%)  75 (31.8)  46 (29.1)  29 (37.2) 
Alanine aminotransferase (U/L) 26.0 (18.0-43.0) 26.0 (18.0-42.0) 26.0 (20.0-43.0) 
    ≤ 50 196 (83.1) 130 (82.3)  66 (84.6) 
    > 50  37 (15.7)  25 (15.8)  12 (15.4) 
Lactate dehydrogenase (U/L) 334.0 (248.0-437.0) 339.0 (247.0-441.5) 329.0 (249.0-411.0) 
    ≤ 245  53 (22.5)  36 (22.8)  17 (21.8) 
    > 245 170 (72.0) 112 (70.9)  58 (74.4) 
Creatine kinase (U/L) 75.5 (47.0-145.0) 75.9 (47.0-131.1) 75.0 (47.0-158.0) 
    ≤ 185 172 (72.9) 118 (74.7)  54 (69.2) 




NEWS2 score at day 1 5.0 (3.0, 7.0) 5.0 (3.0, 7.0) 4.0 (3.0, 6.0) 
Six-category scale at day 1    
2 Hospitalization, not requiring 
supplemental oxygen, n (%) 
3 (1.3)   0   3 (3.8) 
3 Hospitalization, requiring 
supplemental oxygen, n (%) 
194 (82.2) 129 (81.6)  65 (83.3) 
4 Hospitalization, requiring HFNC 
and/or non-IMV, n (%) 
37 (15.7)  28 (17.7)   9 (11.5) 
5 Hospitalization, requiring ECMO 
and/or IMV, n (%) 
1 (0.4)   0   1 (1.3) 
6 Death 1 (0.4)   1 (0.6)   0 
Mean baseline viral load of NP/OP 
swabs (SD), log10 copies/mL 
  4.7 ±2.6   4.7 ±2.8   4.7±2.4 
Receiving injection of interferon 
α2b at day 1, n (%) 
44 (18.6) 29 (18.4) 15 (19.2) 
Receiving lopinavir-ritonavir at day 
1, n (%) 
42 (17.8) 27 (17.1) 15 (19.2) 
Antibiotic at baseline, n (%) 184 (78.0) 121 (76.6)  63 (80.8) 
Corticosteroids therapy at baseline, 
n (%) 
 91 (38.6)  60 (38.0)  31 (39.7) 
Note. Numbers in parenthesis correspond to interquartile range observed value for continuous variables 




Table 2. Any Treatments Received before and after Enrollment. 
Characteristics 
Total  
(n = 236) 
Remdesivir group 
 (n = 158) 
Control group  
(n = 78) 
Days from illness onset to starting drug (days)  10.0 (9.0, 12.0) 11.0 (9.0, 12.0) 10.0 (8.0, 11.0) 
    Early (≤10 days of symptom onset), n (%) 117 (49.6)  70 (44.3)  47 (60.3) 
    Late (> 10 days of symptom onset), n (%) 111 (47.0)  83 (52.5)  28 (35.9) 
Receiving injection of interferon α2b, n (%)  76 (32.2)  46 (29.1)  30 (38.5) 
Receiving lopinavir-ritonavir, n (%)  67 (28.4)  44 (27.8)  23 (29.5) 
Vasopressors, n (%)  38 (16.1)  25 (15.8)  13 (16.7) 
Renal replacement therapy, n (%)   6 (2.5)   3 (1.9)   3 (3.8) 
Highest oxygen therapy support    
Non-invasive mechanical ventilation, n (%)  17 (7.2)  14 (8.9)   3 (3.8) 
Invasive mechanical ventilation, n (%)  21 (8.9)  11 (7.0)  10 (12.8) 
IMV+ECMO, n (%)   2 (0.8)   2 (1.3)   0 
Antibiotic, n (%) 215 (91.1) 142 (89.9)  73 (93.6) 
Corticosteroids therapy, n (%) 155 (65.7) 102 (64.6)  53 (67.9) 
Days from illness onset to corticosteroids therapy (days) 8.5 (6.5, 11.0) 9.0 (7.0, 11.0) 8.0 (6.0, 10.0) 
Days of corticosteroids therapy (days) 10.0 (6.0, 15.0) 9.0 (5.0, 15.0) 10.0 (6.0, 16.0) 
 
Note. Numbers in parenthesis correspond to interquartile range observed value for continuous variables and to percentages for indicator 
variables as appropriate. Abbreviation: NEWS2 = National Early Warning Score 2; HFNC = high-flow nasal cannula for oxygen therapy; IMV 




Table 3. Outcomes in the intention-to-treat population. 
Characteristics 
Total  
(n = 236) 
Remdesivir group (n 
= 158) 
Control group  
(n = 78) 
Difference§ 
TTCI 22.0 (13.5 to 28.0) 21.0 (13.0 to 28.0) 23.0 (15.0 to 28.0) 1.23 (0.87 to 1.75)† 
Day 28 mortality, n (%) 32 (13.6) 22 (13.9) 10 (12.8) 1.1 (-8.1 to 10.3) 
   Early (≤10 days of symptom onset) 15 (6.4) 8 (5.1) 7 (9.0) -3.9 (-11.1 to 3.3) 
   Late (> 10 days of symptom onset) 15 (6.4) 12 (7.6) 3 (3.8) 3.7 (-2.2 to 9.7) 
Clinical improvement rates         
Day 7, n (%) 6 (2.5) 4 (2.5) 2 (2.6) -0.0 (-4.3 to 4.2) 
Day 14, n (%) 60 (25.4) 42 (26.6) 18 (23.1) 3.5 (-8.1 to 15.1) 
Day 28, n (%) 148 (62.7) 103 (65.2) 45 (57.7) 7.5 (-5.7 to 20.7) 
IMV duration (days)  8.0 (5.0 to 19.0) 7.0 (4.0 to 16.0)  15.5 (6.0 to 21.0) 4.0 (-2.0 to 14.0) 
IMV duration in survivors (days) & 30.5 (17.0 to 42.0) 19.0 (5.0 to 42.0) 42.0 (17.0 to 46.0) -12.0 (-41.0 to 25.0) 
IMV duration in non-survivors (days) & 7.0 (4.0 to 15.0) 7.0 (2.0 to 11.0) 8.0 (5.0 to 16.0) 2.5 (-3.0 to 11.0) 
Length of oxygen support (days) 20.0 (12.0 to 31.0) 19.0 (11.0 to 31.0) 21.0 (14.0 to 30.5) 2.0 (-1.0 to 6.0) 
Hospital length of stay (days) 25.0 (16.5 to 37.0) 25.0 (16.0 to 38.0) 24.5 (18.0 to 36.0) 0.0 (-4.0 to 4.0) 
Days from randomization to discharge (days) 21.0 (13.0 to 31.0) 21.0 (12.0 to 31.0) 21.0 (13.5 to 28.5) 0.0 (-3.0 to 3.0) 
Days from randomization to death (days) 11.0 (6.0 to 18.0) 9.5 (6.0 to 18.5) 11.0 (7.0 to 18.0) 1.0 (-5.0 to 7.0) 
Six-category scale at day 7       0.69 (0.41 to 1.17)* 
1 Discharge (alive) 6 (2.5) 4 (2.5) 2 (2.6)   
2 Hospitalization, not requiring supplemental oxygen, n (%) 37 (15.7) 21 (13.3) 16 (20.5)   
3 Hospitalization, requiring supplemental oxygen, n (%) 130 (55.1) 87 (55.1) 43 (55.1)   
4 Hospitalization, requiring HFNC and/or non-IMV, n (%) 34 (14.4) 26 (16.5) 8 (10.3)   
5 Hospitalization, requiring ECMO and/or IMV, n (%) 10 (4.2) 6 (3.8) 4 (5.1)   
6 Death 14 (5.9) 10 (6.3) 4 (5.1)   
Six-category scale at day 14    1.25 (0.76 to 2.04)* 
1 Discharge (alive) 57 (24.2) 39 (24.7) 18 (23.1)   
2 Hospitalization, not requiring supplemental oxygen, n (%) 31 (13.1) 21 (13.3) 10 (12.8)   
3 Hospitalization, requiring supplemental oxygen, n (%) 89 (37.7) 61 (38.6) 28 (35.9)   
4 Hospitalization, requiring HFNC and/or non-IMV, n (%) 21 (8.9) 13 (8.2) 8 (10.3)   
5 
 
5 Hospitalization, requiring ECMO and/or IMV, n (%) 11 (4.7) 4 (2.5) 7 (9.0)   
6 Death 22 (9.3) 15 (9.5) 7 (9.0)   
Six-category scale at day 28    1.14 (0.66 to 1.95)* 
1 Discharge (alive) 136 (57.6) 91 (57.6) 45 (57.7)  
2 Hospitalization, not requiring supplemental oxygen, n (%) 18 (7.6) 14 (8.9) 4 (5.1)  
3 Hospitalization, requiring supplemental oxygen, n (%) 31 (13.1) 18 (11.4) 13 (16.7)  
4 Hospitalization, requiring HFNC and/or non-IMV, n (%) 4 (1.7) 2 (1.3) 2 (2.6)  
5 Hospitalization, requiring ECMO and/or IMV, n (%) 5 (2.1) 2 (1.3) 3 (3.8)  
6 Death 32 (13.6) 22 (13.9) 10 (12.8)  
 
Note. Number (percentage) or median (interquartile range) is summarized as appropriate. Abbreviation: ICU = intensive care unit; HFNC = high-flow nasal oxygen therapy; 
IMV = intensive mechanical ventilation; ECMO = extracorporeal membrane oxygenation; TTCI = time to clinical improvement. Clinical improvement (the event) was defined 
as a decline of two categories on the modified seven-category ordinal scale of clinical status, or hospital discharge.  
* Calculated by ordinal logistic regression model. 
& In survivors, 3 patients were in each group; In non-survivors, 10 patients were in remdesivir group, 7 cases in control group. 
§Differences were expressed as rate differences or Hodges-Lehmann estimator and 95% confidence intervals.  
† The hazard ratio was estimated by COX proportional risk model. 
 
 
Table 4. Summary of adverse events in safety population that occurred in more than one participant  
Events 
Remdesivir group 
(n = 155) 
 Control group  
(n = 78) 
 Any Grade Grade 3 or 4 Any Grade Grade 3 or 4 
Any adverse event (in ≥2% of patients in any treatment group) * 102 (65.8)  13 (8.4)  50 (64.1)  11 (14.1) 
Hypoalbuminemia  20 (12.9)   0  12 (15.4)   1 (1.3) 
Hypokalemia  18 (11.6)   2 (1.3)  11 (14.1)   1 (1.3) 
Increased blood glucose  11 (7.1)   0   6 (7.7)   0 
Anaemia 18 (11.6) 1 (0.6) 12 (15.4) 2 (2.6) 
Rash 11 (7.1) 0 2 (2.6) 0 
Thrombocytopenia 16 (10.3) 4 (2.6) 5 (6.4) 3 (3.8) 
Increased total bilirubin 15 (9.7) 1 (0.6) 7 (9.0) 0 
Elevated blood lipids  10 (6.5)   0   8 (10.3)   0 
Elevated WBC 11 (7.1) 0 6 (7.7) 0 
Hyperlipemia 10 (6.5) 0 8 (10.3) 0 
Increased BUN 10 (6.5) 0 5 (6.4) 0 
Elevated neutrophil 10 (6.5) 0 4 (5.1) 0 
Aspartate aminotransferase increased 7 (4.5) 0 9 (11.5) 0 
Constipation 21 (13.5) 0 12 (15.4) 0 
Nausea 8 (5.2) 0 2 (2.6) 0 
Diarrhoea 5 (3.2) 0 2 (2.6) 0 
Vomiting 4 (2.6) 0 2 (2.6) 0 
Reduced serum sodium   4 (2.6)   0   2 (2.6)   0 
Increased serum potassium   4 (2.6)   2 (1.3)   1 (1.3)   0 
Any serious adverse event* 28 (18.1) 9 (5.8) 20 (25.6) 10 (12.8) 
Respiratory failure or acute respiratory distress syndrome 16 (10.1) 4 (2.6) 6 (7.7) 4 (5.1) 
Cardiopulmonary failure 8 (5.2) 0 7 (9.0) 1 (1.3) 
Pulmonary embolism 1 (0.6) 1 (0.6) 1 (1.3) 1 (1.3) 
Recurrence of COVID-19 1 (0.6) 0 0 0 
Cardiac arrest 1 (0.6) 0 0 0 
Acute coronary syndrome 0 0 1 (1.3) 1 (1.3) 
Tachycardia 0 0 1 (1.3) 0 
 
 
Septic shock 1 (0.6) 0 1 (1.3) 1 (1.3) 
Lung abscess 0 0 1 (1.3) 1 (1.3) 
Sepsis 0 0 1 (1.3) 1 (1.3) 
Bronchitis 0 0 1 (1.3) 1 (1.3) 
Thrombocytopenia 1 (0.6) 1 (0.6) 0 0 
Increased D-dimer 0 0 1 (1.3) 1 (1.3) 
Hemorrhage of lower digestive tract 1 (0.6) 1 (0.6) 0 0 
Ileus 0 0 1 (1.3) 0 
Deep vein thrombosis 1 (0.6) 1 (0.6) 1 (1.3) 1 (1.3) 
Acute kidney injury 1 (0.6) 0 0 0 
Diabetic keto-acidosis 0 0 1 (1.3) 1 (1.3) 
Multiple organ dysfunction syndrome 1 (0.6) 0 2 (2.6) 0 
Any AE/SAE leading to discontinued drug  18 (11.6)   3 (1.9)   4 (5.1)   1 (1.3) 
Respiratory failure or acute respiratory distress syndrome    7 (4.5)  1 (0.6) 1 (1.3)   0 
Cardiopulmonary failure   3 (1.9)   0   1 (1.3)   0 
Nausea   1 (0.6)   0   0   0 
Vomiting   1 (0.6)   0   0   0 
Ileus   0   0   1 (1.3)   0 
Elevated ALT    2 (1.3)   1 (0.6)   0   0 
Rash   2 (1.3)   0   0   0 
Poor appetite   1 (0.6)   0   0   0 
Increased total bilirubin   1 (0.6)   0   0   0 
Acute kidney injury   1 (0.6)   1 (0.6)   0   0 
Seizure   0   0   1 (1.3)   0 
Aggravated schizophrenia   0   0   1 (1.3)   1 (1.3) 
Aggravated depression   0   0   1 (1.3)   1 (1.3) 
Data are n (%) and include all events reported after antiviral treatment.  
*Some patients had more than one adverse event. 
§Totally,36 patients discontinued the drug, 22 cases for AE/SAE, 14 patients for other reason (such as hospital discharge or early death). Detailed 
individual reasons for drug discontinuing was listed in appendix.
 
 
Figure 1. Trial profile  
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4 Withdrew
158 Were assigned to the remdesivir
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78 Were assigned to the control group 
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3 Did not receive remdesivir
5 Receive remdesivir< 5 days





 Figure 2. Kaplan Meier of time-to-clinical improvement in the Intention-to-Treat Population during 
the 28 days. 
 
 
Note. Benefit ratio (BR) for clinical improvement was 1.23; 95% confidence interval [CI], 0.87 to 
1.75; The adjusted BR for randomization stratification was 1.25; 95% CI 0.88 to 1.78. 
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BR 1.23 (0.87, 1.75);





Figure 3. SARS-CoV-2 load by qPCR on the upper (nasopharyngeal or oropharyngeal swabs) (Panel 
A) /lower (Panel B) respiratory tract specimens (data only from viral positive population). 
 
Data were presented mean (±SE). Results less than the lower limit of quantification of PCR assay and 
greater than the limit of qualitative detection are imputed with half of actual value log10 copies/mL; 
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